vMedex, Inc. v. TDS Operating, Inc.

CourtDistrict Court, D. Delaware
DecidedAugust 21, 2020
Docket1:18-cv-01662
StatusUnknown

This text of vMedex, Inc. v. TDS Operating, Inc. (vMedex, Inc. v. TDS Operating, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
vMedex, Inc. v. TDS Operating, Inc., (D. Del. 2020).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE VMEDEX, INC., NEURON DYNAMICS, ) LLC, BRENT PATTON, LORRAINE ) GROSSO, JOSEPH GROSSO, ROBERT ) NIXON, ERIC WESTBROOK, GARTH ) SCHNEIDER, MARK MCCURRY, CURT ) VAN CALSTER, JEFFREY WICKMAN, ) ) Plaintiffs, ) ) v. ) C.A. No. 18-1662 (MN) ) TDS OPERATING, INC., TRANSACTION ) DATA SYSTEMS, INC., RX30 ) HOLDINGS, LLC, GTCR, LLC, JUDE ) DIETERMAN, STEVE WUBKER, ) ) Defendants. )

MEMORANDUM OPINION Ann M. Kashishian, KASHISHIAN LAW LLC, Wilmington, Delaware. Marlo J. Hittman, LAW OFFICE OF MARLO J. HITTMAN, Livingston, NJ. Counsel for Plaintiffs.

Marc S. Casarino, WHITE & WILLIAMS LLP, Wilmington, Delaware. David M. Friebus, BAKER & HOSTETLER LLP, Chicago, Illinois. Counsel for Defendants.

August 21, 2020 Wilmington, Delaware ee. Marge sike Plaintiffs vMedex, Inc. (“vMedex”’) and Neuron Dynamics, LLC (“Neuron”), and Brent Patton, Lorraine Grosso, Joseph Grosso, Robert Nixon, Eric Westbrook, Garth Schneider, Mark McCurry, Curt Van Calster, and Jeffrey Wickman (collectively, “Individual Plaintiffs”) have sued Defendants TDS Operating, Inc. (“TDS Operating”), Transaction Data Systems, Inc. (“Transaction Data’), Rx30 Holdings, LLC (“Rx30”), GTCR, LLC (‘GTCR”) (collectively, “Entity Defendants”), and Jude Dieterman and Steve Wubker, alleging seven counts of contract and tort liabilities related to asset purchase and employment agreements and one count for violation of the Age Discrimination in Employment Act (‘ADEA”).' Defendants filed a Motion to Dismiss Plaintiffs’ Second Amended Complaint for failure to state a claim under Rule 12(b)(6) of the Federal Rules of Civil Procedure. This Court has subject matter jurisdiction pursuant to 28 U.S.C. § 1331 for the claims arising under the ADEA, and pursuant to 28 U.S.C. § 1332 for the remaining claims. For the following reasons, Defendants’ Motion to Dismiss is GRANTED-IN- PART and DENIED-IN-PART. I. BACKGROUND The facts alleged are as follows: A. The Parties Plaintiff vMedex is a Nevada corporation that provided medication therapy management software to pharmacies. (D.I. 44 J 25, 114). Plaintiff Neuron is a Nevada limited liability company and the majority shareholder of vMedex. (Ud. J] 26, 27). All Individual Plaintiffs other than Brent Patton were affiliated with vMedex and served in technical or operational roles for vMedex, Neuron, or both. Ud. 9] 37, 117). All Individual Plaintiffs other than Brent Patton and

The Counts are labeled I-IX but Count IV was “intentionally omitted.”

Lorraine Grosso were equity holders of vMedex, Neuron, or both. (Id. ¶ 119). Individual Plaintiffs were hired by Defendants in or around 2016. (Id. ¶¶ 182–84). Defendant TDS Operating is a Delaware corporation. (Id. ¶ 40). Defendant Transaction Data is a Florida corporation and the controlling shareholder of TDS Operating. (Id. ¶¶ 41, 66).

Defendant Rx30 is a Delaware limited liability corporation and, through a series of intermediaries, the controlling shareholder of Transaction Data. (Id. ¶¶ 42, 63–65). Defendant GTCR is a Delaware limited liability company and the sole owner of both Transaction Data and Rx30. (Id. ¶¶ 43, 44). Defendant Jude Dieterman is the current President and CEO of Transaction Data, doing business as Rx30, (id. ¶ 166), holding positions formerly held by Defendant Steve Wubker, (id. ¶¶ 166, 388). At the direction of TDS Operating, Transaction Data, and Rx30, certain Individual Plaintiffs authored a computer program called StarGuard, to be used by subscribers to the Rx30 pharmaceutical software platform. (Id. ¶ 115). StarGuard provided pharmacies with practice management services and tools to assure compliance with performance obligations imposed by

government reimbursement programs and insurance providers. (Id. ¶ 117). StarGuard was integrated into the Rx30 software and deployed through the Rx30 interface. (Id.). This business arrangement was memorialized in a Joint Venture Agreement between vMedex and Transaction Data on August 15, 2014. (Id. ¶ 120). B. The Asset Purchase Agreement In 2016, after a dispute over the Joint Venture Agreement arose between parties, Steve Wubker proposed a new agreement. (Id. ¶ 135). Wubker proposed that vMedex sell its assets to TDS Operating, which, through its affiliates, could expand the reach of vMedex products. (Id. ¶¶ 139–42). TDS Operating, vMedex, and Neuron entered into an Asset Purchase Agreement (“APA”) on April 1, 2016, under which vMedex and Neuron sold to TDS Operating assets including StarGuard. The APA forgave all amounts due under the Joint Venture Agreement and rendered the Joint Venture Agreement null and void. (D.I. 47, Ex. B § 2.2). Under the APA, TDS Operating was to pay vMedex and Neuron $1 million at closing in consideration for the asset purchase. (Id. § 2.1). vMedex and Neuron were also eligible to receive

earn-out payments based on the number of customers – defined as unique pharmacy stores in good standing – licensing their software products or services at the end of 2017 and 2018. (Id. § 2.3). If TDS Operating elected to bundle the purchased software with other products or services offered by TDS Operating, a customer of the bundled software would count toward the customer base for purposes of calculating the earn-out payments to vMedex and Neuron. (Id. § 2.3.3). The earn-out payments were calculated as $6,000 for every customer that exceeded a certain threshold by the last day of the year, up to a certain cap. For 2017, the threshold was 1,250 stores, with the payment capped at $1.5 million (250 stores above the threshold) (“2017 Earn- Out”). (Id. § 2.3.1(a)–(b)). For 2018, the threshold was 2,000 stores, with the payment capped at $1.5 million. (Id. § 2.3.2(a)–(b)). But if vMedex and Neuron had earned the maximum amount

under the 2017 Earn-Out and had at least 2,500 customers by the end of 2018, vMedex and Neuron would be entitled to a payment of $1.9 million (“2018 Earn-Out”). (Id.). TDS Operating was to provide statements of the year-end earn-out payment calculations no later than March 31 of the following year, with payment to follow within five business days. (Id. §§ 2.3.1, 2.3.2, 2.5). Upon receipt of this statement, vMedex and Neuron would have 30 days to inspect “any books and records related to the 2017 Customer Base or the 2018 Customer Base, as applicable, upon reasonable notice to [TDS Operating].” (Id. § 2.4). Within this 30-day period, vMedex and Neuron could object to the earn-out calculation via a written notice, which would initiate a process of negotiations and arbitration or litigation between parties. (Id.). In any such arbitration or litigation, the non-prevailing party would be liable to pay the collection costs of the prevailing party. (Id.). The APA also imposes on TDS Operating a duty to consult with vMedex and Neuron on the marketing and distribution of their products, but otherwise gives TDS Operating free rein over

business decisions pertaining to the acquired assets: The Buyer [TDS Operating] will consult with representatives of the Seller [vMedex and Neuron], in good faith, regarding the appropriate marketing and distribution strategies for maximizing the 2017 Customer Base and the 2018 Customer Base, as applicable. However, notwithstanding the foregoing, the Parties acknowledge and agree that following the Closing, the Buyer shall have absolute discretion with regard to all matters relating to the operation of the Business. (Id. § 2.6). The APA designates Delaware law to resolve disputes over the contract. (Id. § 9.11). C.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Gross v. FBL Financial Services, Inc.
557 U.S. 167 (Supreme Court, 2009)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Mayer v. Belichick
605 F.3d 223 (Third Circuit, 2010)
Coface Collections North America Inc. v. William Newton
430 F. App'x 162 (Third Circuit, 2011)
Morse v. Lower Merion School District
132 F.3d 902 (Third Circuit, 1997)
Lorillard Tobacco Co. v. American Legacy Foundation
903 A.2d 728 (Supreme Court of Delaware, 2006)
H-M Wexford LLC v. Encorp, Inc.
832 A.2d 129 (Court of Chancery of Delaware, 2003)
Anderson v. Wachovia Mortgage Corp.
497 F. Supp. 2d 572 (D. Delaware, 2007)
Shearin v. E.F. Hutton Group, Inc.
652 A.2d 578 (Court of Chancery of Delaware, 1994)
E.I. DuPont De Nemours & Co. v. Pressman
679 A.2d 436 (Supreme Court of Delaware, 1996)
Nemec v. Shrader
991 A.2d 1120 (Supreme Court of Delaware, 2010)
Kuroda v. SPJS Holdings, L.L.C.
971 A.2d 872 (Court of Chancery of Delaware, 2009)
Travelers Indemnity Co. v. Lake
594 A.2d 38 (Supreme Court of Delaware, 1991)
Allied Capital Corp. v. GC-Sun Holdings, L.P.
910 A.2d 1020 (Court of Chancery of Delaware, 2006)
Lord v. Souder
748 A.2d 393 (Supreme Court of Delaware, 2000)
Annan v. Wilmington Trust Co.
559 A.2d 1289 (Supreme Court of Delaware, 1989)

Cite This Page — Counsel Stack

Bluebook (online)
vMedex, Inc. v. TDS Operating, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/vmedex-inc-v-tds-operating-inc-ded-2020.